Business
Avenacy Provides Update on Business Progress and Announces 2026 Strategic Priorities Ahead of 44th Annual J.P. Morgan Healthcare Conference
SCHAUMBURG, Ill., January 08, 2026--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today provided an update on recent business highlights and financial performance for 2025 and strategic priorities for 2026 ahead of the Company’s participation in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026 in San Francisco, CA.
About this update from Jp Morgan Chase & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1768,"height":262,"url":"https://media.zenfs.com/en/business-wire.com/e864c93731db0c5aaaab673863d9466c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Hq9Vye66DMZUb1p0ncuBzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE0MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e864c93731db0c5aaaab673863d9466c","width":960,"height":142},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/HqE3vD3gXC6NAjdchBMiPw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zNTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e864c93731db0c5aaaab673863d9466c","width":1200,"height":178}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Achieved goal of launching 25 products by year-end 2025, with over 3 million units sold since January 2024","length":106,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"On track to achieve 200%+ FY2025 YoY revenue growth and 300%+ FY2025 YoY gross profit expansion","length":95,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Well-capitalized to continue executing on near-term critical injectable product launches while pursuing strategic portfolio expansion that supports the Company’s long-term growth objectives","length":189,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":390,"olType":false},{"type":"text","content":"SCHAUMBURG, Ill., January 08, 2026--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today provided an update on recent business highlights and financial performance for 2025 and strategic priorities for 2026 ahead of the Company’s participation in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026 in San Francisco, CA.","length":411,"tagName":"p"},{"type":"text","content":""2025 marked Avenacy’s second full year of operations, where we once again delivered outstanding progress and reinforced our standing as a leading partner for hospitals and providers in need of essential medications. With 25 products launched in two years, our pace of commercial execution and financial growth is redefining excellence in the specialty pharmaceutical industry," said Jeff Yordon, Co-Founder & CEO of Avenacy. &quo...